Aktienanalyse zu Xtant Medical Holdings Inc (XTNT)XTNTXtant Medical Holdings Inc

Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Xtant Medical Holdings Inc (XTNT) appears to be a good buy right now due to its recent positive developments and strong potential for growth. The stock has experienced a significant 5-day change of +18.19%, indicating strong short-term momentum. Additionally, the company has raised its 2026 revenue guidance to between $101 million and $105 million, reflecting confidence in its growth trajectory. However, the main risk is the current high RSI of 76.805, which suggests that the stock may be overbought in the short term.

2 analysts cover XTNT: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 1.50.